argenx SE American Depositary Receipt

argenx SE American Depositary Receipt is an American depositary receipt representing shares of argenx SE, a Netherlands-based biopharmaceutical company focused on developing and commercializing antibody-based therapies for severe autoimmune and neuromuscular diseases. The company’s current portfolio centers on immunology medicines, including treatments for generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. argenx also advances a broader pipeline of differentiated antibody therapeutics built on its proprietary Simple Antibody platform, which supports research across autoimmune and other specialty disease areas. As an ADR, it gives U.S. market participants a way to access argenx’s underlying equity exposure through a familiar U.S.-traded security. The asset is closely tied to the global biotechnology and healthcare markets, where demand for specialized biologic therapies continues to shape commercial and clinical activity.